Sorux Expands Bio Business with CHA Vaccine Institute Acquisition... Establishes Mid- to Long-Term Growth Foundation

Sorux is set to launch a full-fledged growth strategy centered on bio-businesses, following its acquisition of management control of CHA Vaccine Institute.

On March 19, Sorux announced that it had secured management control of CHA Vaccine Institute, explaining that the deal is not a simple investment but a strategic decision aimed at enhancing the group’s overall growth structure. Under the terms of the agreement, Sorux is participating as the entity acquiring management control.

Founded in 1995, Sorux has established a stable business foundation through its LED business, focusing on indoor, outdoor, and specialty lighting. Building on this, the company has pursued portfolio diversification to secure future growth engines, and this latest acquisition is interpreted as a strategic extension of its effort to combine the stability of its existing business with the growth potential of bio-assets.

CHA Vaccine Institute, a KOSDAQ-listed affiliate of CHA Bio Group, possesses a diverse vaccine pipeline centered on its L-pampo™ and Lipo-pam™ immuno-enhancement platforms. In particular, its proprietary immuno-adjuvant Lipo-pam™ has been included in the Coalition for Epidemic Preparedness Innovations (CEPI) vaccine adjuvant library, and the company is currently developing therapeutic vaccines for hepatitis B and shingles.

Sorux is also expecting to generate synergy with Aribio, in which it is the largest shareholder. Aribio has established global clinical competitiveness with its Alzheimer’s treatment AR1001, and its global Phase 3 clinical trial (POLARIS-AD), currently underway in 13 countries including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), has progressed more than 90% as of the article's publication date.

The company emphasizes that Aribio and CHA Vaccine Institute have been built not as simple parallel structures, but as an organically connected bio-axis. Aribio holds late-stage clinical assets in the central nervous system disease field, while CHA Vaccine Institute possesses immune modulation and vaccine platform technologies, creating opportunities for synergy in joint research and development, technology commercialization, and partnership expansion.

With this move, Sorux has transitioned from a single pipeline focus to securing multiple growth axes, namely therapeutics for degenerative brain diseases and immune/vaccine platforms. By simultaneously holding assets at different development and commercialization stages, the company is expected to achieve both risk diversification and expansion of its growth story.

A Sorux representative stated, “This acquisition is a strategic turning point that goes beyond simply adding a bio-asset—it sets the direction for enhancing corporate value. Through Aribio and CHA Vaccine Institute, we have established a structure encompassing the neurodegenerative disease and immune/vaccine sectors.”

The representative added, “The technologies and pipelines of both companies are highly complementary, so we expect strong synergy. Based on our existing business foundation, we will organically link bio-assets to build a mid- to long-term value growth structure that is tangible in the market.”

Meanwhile, Sorux plans to further refine its group-level strategies and business collaboration systems, while simultaneously pursuing both independent growth and joint business opportunities for each affiliate.

This content was produced with the assistance of AI translation services.